Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (NASDAQ: CLLS) reported final Phase 1 BALLI-01 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary NATHALI-01 data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026.
Lasme-cel achieved 100% ORR (7/7) in the target Phase 2 population, with 57% CR/CRi and 75% MRD-negative among responders; all proceeded to HSCT. ≥grade 3 CRS and ICANS each occurred in 4% of patients, IEC-HS in 2%, all resolving. Eti-cel showed 88% ORR and 63% CR in the optimal dose cohort, with alemtuzumab exposure and low-dose IL-2 being explored to optimize lymphodepletion and CAR-T expansion. Both BALLI-01 pivotal Phase 2 and NATHALI-01 Phase 1 are open for recruitment, with key analyses expected in Q4 2026.
Cellectis (NASDAQ: CLLS) received FDA RMAT designation for lasmecabtagene timgedleucel (lasme-cel), a CD22-targeting allogeneic CAR-T candidate for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
The designation is based on Phase 1 BALLI-01 data and supports the ongoing pivotal Phase 2 BALLI-01 trial, which is open for enrollment.
Cellectis (CLLS) reported its monthly share capital and voting rights information for Euronext Growth.
As of May 31, 2026, the company had 100,691,658 shares outstanding and a total of 106,134,467 voting rights (ISIN: FR0010425595).
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on Cellectis’ investor website.
Cellectis (NASDAQ: CLLS) will present new clinical data on its allogeneic CAR-T candidates lasme-cel and eti-cel at the EHA 2026 congress in Stockholm, June 11–14, 2026.
Presentations cover full Phase 1 BALLI-01 data in r/r B-ALL and preliminary Phase 1 NATHALI-01 data in r/r B-NHL, with broader datasets expected in Q4 2026.
Summary not available.
Cellectis (Euronext Growth: CLLS) published its monthly statement of share capital and voting rights as of 04/30/2026. The table shows a total of 100,611,481 shares and 106,021,715 total voting rights.
Contact details for media and investor relations are provided.
Cellectis (NASDAQ: CLLS) said it will release its first-quarter 2026 financial results for the period ended March 31, 2026 on May 11, 2026 after U.S. market close. The company also said it will not host a conference call; the press release will be posted on its investor website and investor relations can be contacted by email.
Cellectis (NASDAQ: CLLS) will present research on a TALE-based epigenetic editing platform at the ASGCT Annual Meeting (May 11–15, 2026) in Boston.
Poster title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2. The approach achieved >90% reduction in gene activity for two targets; poster available May 13, 2026 at 5 PM ET.
Cellectis (NASDAQ: CLLS) highlighted interim futility analysis data from Allogene’s pivotal ALPHA3 trial of cema-cel in first-line consolidation for large B-cell lymphoma. The Day 45 MRD cutoff showed 58.3% MRD negativity with cema-cel vs 16.7% with observation, a 41.6% absolute difference.
Allogene reported favorable tolerability (no CRS, ICANS, GvHD, or treatment-related SAEs) and expects accrual complete by end-2027, interim EFS analysis mid-2027 and primary EFS analysis mid-2028. Cellectis may receive up to $340M in milestones plus low double-digit royalties on licensed CD19 products.